This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain

SAN FRANCISCO, April 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate. NKTR-192 is designed to have a short-acting profile with rapid onset of pain relief for the treatment of acute pain. With a reduced rate of entry into the central nervous system (CNS) as compared to other fast-acting opioid therapies in preclinical studies, NKTR-192 has the potential to greatly reduce the euphoria that underlies opioid abuse and dependence, as well as other unwanted CNS side effects, such as sedation. The unique characteristics of NKTR-192 are engineered into its new molecular design and are not the result of formulation techniques.

The single-dose Phase 1 clinical study will assess the pharmacokinetics and safety of NKTR-192 in up to 36 healthy subjects. The primary objective of the study is to assess the pharmacokinetic profile of various dosages in humans in order to design future clinical studies for the compound. This Phase 1 clinical study is being conducted in the United States at Lifetree Clinical Research.

"With prescription opioid abuse at epidemic levels in the United States, new approaches are desperately needed to address this serious problem," said Robert Medve, M.D., Chief Medical Officer of Nektar Therapeutics. "NKTR-192 is a highly compelling new opioid molecule that has exceeded our expectations in multiple preclinical studies. The drug candidate demonstrated a fast onset of analgesia, while at the same time showing greatly reduced abuse liability and sedation as compared to standard short-acting opioids. NKTR-192 is an excellent addition to Nektar's pain portfolio, and we look forward to evaluating this new mu-opioid analgesic molecule in the clinic."

Preclinical data for NKTR-192 was highlighted last November at the Society for Neuroscience Annual Meeting: Neuroscience 2011. Data from in vivo and in vitro studies demonstrated that NKTR-192 exhibits onset of analgesic activity within five minutes, as well as a peak effect comparable to current opioids. In preclinical models used to predict the abuse liability of compounds, NKTR-192 shows a marked reduction in self-administration of NKTR-192 as compared to reference opioids. Additionally, NKTR-192 exhibits a significantly reduced rate of entry into the CNS as compared to leading opioid agents.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.37%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $238.90 -1.20%
YHOO $36.53 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs